KORU Medical Systems (NASDAQ:KRMD) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

KORU Medical Systems (NASDAQ:KRMD) issued its quarterly earnings results on Wednesday. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03, Zacks reports. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The firm had revenue of $12.05 million for the quarter, compared to analyst estimates of $11.62 million.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q2 revenue reached a record $12 million, up 18% year over year, driven by 12% growth in domestic core revenue and 59% international growth. Management said domestic demand, patient retention, new starts, and market-share gains remain strong.
• Gross margin improved to 65.1% from 63.5% a year ago, supported by manufacturing efficiencies, pricing, mix, and improved supplier terms. KORU also reported positive net income for the first time since 2019, positive operating cash flow in the quarter, and reiterated expectations for positive adjusted EBITDA for the full year.
• The company narrowed 2026 revenue guidance to $47.5 million-$48.5 million from its prior outlook, citing slower-than-expected launches in certain international, non-tender markets. Management now expects some of that prefilled-syringe opportunity to contribute more meaningfully in 2027.
• KORU withdrew its U.S. PHESGO 510(k) application after discussions with the FDA and will pursue other oncology biologics instead, delaying its planned U.S. oncology entry. PHESGO remains part of the international strategy, but additional real-world evidence and regulatory work are required.
• The company acquired connected-monitoring technology intended to add adherence tracking, real-world evidence, and patient support to its infusion platform, though management characterized it as a multi-year development effort. KORU also said Freedom 360 development has cleared its highest-risk stages and remains on track for a U.S. 510(k) submission by the end of 2027.

KORU Medical Systems Stock Down 13.8%

NASDAQ:KRMD traded down $0.57 during mid-day trading on Thursday, reaching $3.56. 1,074,221 shares of the stock were exchanged, compared to its average volume of 166,686. The company has a 50 day simple moving average of $4.13 and a 200-day simple moving average of $4.39. The stock has a market capitalization of $163.52 million, a P/E ratio of -71.20 and a beta of 0.45. KORU Medical Systems has a 1 year low of $3.21 and a 1 year high of $6.61.

Analyst Upgrades and Downgrades

KRMD has been the topic of a number of recent research reports. Craig Hallum restated a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a research report on Thursday. Weiss Ratings raised KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded KORU Medical Systems from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, KORU Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $7.00.

Insider Buying and Selling at KORU Medical Systems

In other news, insider Adam R. Kalbermatten acquired 12,500 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $3.94 per share, with a total value of $49,250.00. Following the completion of the acquisition, the insider owned 312,500 shares of the company’s stock, valued at $1,231,250. The trade was a 4.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 28,000 shares of company stock valued at $109,430 over the last three months. 18.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On KORU Medical Systems

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of KORU Medical Systems by 101.3% during the 2nd quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock valued at $3,571,000 after acquiring an additional 501,875 shares during the period. First Light Asset Management LLC increased its stake in KORU Medical Systems by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock valued at $16,760,000 after purchasing an additional 226,700 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in KORU Medical Systems by 189.5% in the first quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock valued at $617,000 after purchasing an additional 158,914 shares during the last quarter. State Street Corp increased its position in shares of KORU Medical Systems by 32.6% in the fourth quarter. State Street Corp now owns 602,645 shares of the company’s stock valued at $3,501,000 after buying an additional 148,166 shares in the last quarter. Finally, Informed Momentum Co LLC purchased a new stake in shares of KORU Medical Systems in the 4th quarter worth about $794,000. 58.60% of the stock is owned by institutional investors and hedge funds.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.